Get the Stockscreener App
1.29
1.57%
0.02
After Hours:
1.35
0.06
+4.65%
Mira Pharmaceuticals Inc stock is traded at $1.29, with a volume of 131.32K.
It is up +1.57% in the last 24 hours and down -25.43% over the past month.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
See More
Previous Close:
$1.27
Open:
$1.28
24h Volume:
131.32K
Relative Volume:
0.09
Market Cap:
$21.36M
Revenue:
-
Net Income/Loss:
$-12.78M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-4.71M
1W Performance:
-2.27%
1M Performance:
-25.43%
6M Performance:
+46.78%
1Y Performance:
-65.14%
1-Day Range:
$1.25
$1.2998
1-Week Range:
$1.23
$1.425
52-Week Range:
$0.51
$5.01
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Compare MIRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.29 | 21.36M | 0 | -12.78M | -4.71M | -0.8815 |
|
LLY
Lilly Eli Co
|
795.35 | 755.90B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
106.80 | 474.49B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
155.01 | 353.35B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
182.93 | 323.26B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
101.64 | 257.11B | 63.17B | 12.15B | 14.84B | 4.77 |
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
Mira Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia
Mira Pharmaceuticals appoints new board member - Investing.com India
MIRA Pharmaceuticals Appoints New Board Member and Chairman - TipRanks
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site - AccessWire
Mira Pharmaceuticals (MIRA) Price Target Increased by 37.58% to 23.15 - MSN
MIRA Pharma up 27% on ketamine analogue’s preclinical results for chemotherapy pain - Mugglehead
MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials - Yahoo Finance
CECO (NASDAQ:CECO) Reports Sales Below Analyst Estimates In Q3 Earnings, Stock Drops 10.6% - Barchart
SoFi Stock Jumps As CEO Hails 'Strongest Quarter In Our History': Retail Confidence Grows - Barchart
Here's What To Expect From Cintas' Next Earnings Report - Barchart
H&E Equipment Services (NASDAQ:HEES) Misses Q3 Sales Targets - Barchart
Janus (NYSE:JBI) Misses Q3 Sales Targets, Stock Drops 13.2% - Barchart
What To Expect From NVIDIA's Next Quarterly Earnings Report - Barchart
What You Need To Know Ahead Of Applied Materials' Earnings Release - Barchart
Small And Micro-Cap Movers: Key News, Market Reactions, And Insider Chatter - Barchart
Warren Buffett Loves SiriusXM, But These 2 Media Stocks Are Better Buys - Barchart
Tiny Healthcare Stock With $35 Million Market Cap Becomes Major Player Overnight In Rapidly Growing $1 Billion Market - Barchart
Teladoc (TDOC) To Report Earnings Tomorrow: Here Is What To Expect - Barchart
Winners For 2024 Webster Awards Announced - Barchart
Becton, Dickinson And Company Earnings Preview: What To Expect - Barchart
ICP DAS-BMP Introduces Latest TPU Materials to Transform Healthcare at COMPAMED 2024 - Barchart
1 'Strong Buy' Dividend Stock That Insiders Are Buying - Barchart
Wheat Posts Monday Losses - Barchart
Beyfortus® Immunization To Protect Infants From RSV Has Begun - Barchart
Weil Group Commences Helium Production From New Alberta Facility - Barchart
F5 (NASDAQ:FFIV) Surprises With Q3 Sales, Stock Soars - Barchart
CRTC approves Google's application and paves way for annual $100 million contribution to Canadian news organizations - Barchart
Transcat (NASDAQ:TRNS) Reports Sales Below Analyst Estimates In Q3 Earnings - Barchart
Tapestry, Capri File Notice To Appeal Court Decision Blocking Their $8.5 Billion Merger - Barchart
PSP Services Inc. Announces Agreement to Acquire the NCR Atleos Debit Card Production and Transaction Processing Business in Canada - Barchart
End of the 2024 cruise season: the Port of Montreal bolsters its status as a must-visit destination in North America - Barchart
AI Platform Haiper Launches Powerful 2.0 Video Model For Increased Realism And Faster Generations - Barchart
Hologic's Quarterly Earnings Preview: What You Need To Know - Barchart
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain - Yahoo Finance
YUL Passengers Now Have Access To CATSA's New CT Technology - Barchart
Canadian-led high seas mission finds illegal harvesting of shark fins and "dark vessels" in North Pacific - Barchart
Why Is MicroStrategy (MSTR) Stock Rocketing Higher Today - Barchart
Autonomix’s Stock Rallies On Strong Trial Results: Retail Sentiment Soars - Barchart
Should You Buy Microsoft Stock Before It Reports Earnings? - Barchart
What You Need To Know Ahead Of Micron Technology's Earnings Release - Barchart
3 Stocks That Goldman Sachs Expects To Beat The Market In 2025 - Barchart
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - Barchart
Here's What To Expect From Accenture's Next Earnings Report - Barchart
Apple, Microsoft, Google, Meta, Amazon: How’s Retail Feeling About These Big Tech Stocks Ahead Of Earnings This Week? - Barchart
CMA Calls For Elimination Of Sick Note Requirements By Employers - Barchart
Hope for Chemo Patients: New Pre-Clinical Study Shows Mira Pharmaceuticals Ketamir-2 Beats Competitors' Chemo Pain Reduction by Over 60% - Barchart
Stock market today: Rising tech stocks send Nasdaq to a record as most of Wall Street stumbles - Barchart
Ketamir-2 shows promise in preclinical pain study - Investing.com India
MAXSUN 800 SERIES MOTHERBOARD LAUNCH EVENT HELD IN BEIJING - Barchart
Soleno Therapeutics To Participate In Upcoming November Investor Conferences - Barchart
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain - Brazosport Facts
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):